Strategies for improving drug delivery: nanocarriers and microenvironmental priming

References

• Looking back on the millennium in medicine. N Engl J Med. 2000;342(1):42–49.
   PubMed Web of Science ®Google Scholar
• Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329–340.
   PubMed Web of Science ®Google Scholar
• Gentile E, Cilurzo F, Di Marzio L, et al. Liposomal chemotherapeutics. Future Oncol. 2013;9:1849–1859.
   PubMed Web of Science ®Google Scholar
• Molinaro R, Wolfram J, Federico C, et al. Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin Drug Deliv. 2013;10(12):1653–1668.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Shen H, Ferrari M. Multistage vector (MSV) therapeutics. J Control Release. 2015;219:406–415.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Zhu M, Yang Y, et al. Safety of nanoparticles in medicine. Curr Drug Targets. 2015;16(14):1671–1681.
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Translational Med. 2016;1(1):10–29.
   PubMed Web of Science ®Google Scholar
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil(R)–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–1598.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Park JW, Yoon IS, et al. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomed. 2014;9:495–504.
   PubMed Web of Science ®Google Scholar
• Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12(11):2301–2308.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 2008;346(1–2):143–150.
   PubMed Web of Science ®Google Scholar
• Chau Y, Dang NM, Tan FE, et al. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. J Pharm Sci. 2006;95(3):542–551.
   PubMed Web of Science ®Google Scholar
• Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;201:78–89.
   PubMed Web of Science ®Google Scholar
• Ohara Y, Oda T, Yamada K, et al. Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int J Cancer. 2012;131(10):2402–2410.
   PubMed Web of Science ®Google Scholar
• Kennel SJ, Woodward JD, Rondinone AJ, et al. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo. Nucl Med Biol. 2008;35(4):501–514.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Farhangrazi ZS. Nanomedicine and the complement paradigm. Nanomedicine. 2013;9(4):458–460.
   PubMed Web of Science ®Google Scholar
• Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 2012;19(6):367–373.
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198–205.
   PubMed Web of Science ®Google Scholar
• Florence AT. “Targeting” nanoparticles: the constraints of physical laws and physical barriers. J Control Release. 2012;164(2):115–124.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.
   Web of Science ®Google Scholar
• Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28(4):181–188.
   PubMed Web of Science ®Google Scholar
• Michor F, Liphardt J, Ferrari M, et al. What does physics have to do with cancer? Nat Rev Cancer. 2011;11(9):657–670.
   PubMed Web of Science ®Google Scholar
• Koay EJ, Ferrari M. Transport Oncophysics in silico, in vitro, and in vivo. Preface Phys Biol. 2014;11(6):060201.
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015 Sep 8;33(9):941–951.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Yang Y, Shen J, et al. The nano-plasma interface: implications of the protein corona. Colloids Surf B Biointerfaces. 2014;124:17–24.
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772–781.
   PubMed Web of Science ®Google Scholar
• Patel HM, Moghimi SM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv Drug Deliv Rev. 1998;32(1–2):45–60.
   PubMed Web of Science ®Google Scholar
• Yona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system - the unaccounted years. Front Immunol. 2015;6:328.
   PubMed Web of Science ®Google Scholar
• Gustafson HH, Holt-Casper D, Grainger DW, et al. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510.
   PubMed Web of Science ®Google Scholar
• Mahon E, Salvati A, Baldelli Bombelli F, et al. Designing the nanoparticle-biomolecule interface for “targeting and therapeutic delivery”. J Control Release. 2012;161(2):164–174.
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Cavaliere C, et al. Analytical methods for characterizing the nanoparticle–protein corona. Chromatographia. 2014;77(11):755–769.
   Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Caruso G, et al. Analysis of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-CHIP coupled to a Q-TOF mass spectrometer. Anal Bioanal Chem. 2010;398(7–8):2895–2903.
   PubMed Web of Science ®Google Scholar
• Kelly PM, Aberg C, Polo E, et al. Mapping protein binding sites on the biomolecular corona of nanoparticles. Nat Nanotechnol. 2015;10(5):472–479.
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Caruso G, et al. Differential analysis of “protein corona” profile adsorbed onto different nonviral gene delivery systems. Anal Biochem. 2011;419(2):180–189.
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Caruso G, et al. Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins. Anal Bioanal Chem. 2013;405(2–3):635–645.
   PubMed Web of Science ®Google Scholar
• O’Connell DJ, Bombelli FB, Pitek AS, et al. Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials. Nanoscale. 2015;7(37):15268–15276.
   PubMed Web of Science ®Google Scholar
• Zhang J, Landry MP, Barone PW, et al. Molecular recognition using corona phase complexes made of synthetic polymers adsorbed on carbon nanotubes. Nat Nanotechnol. 2013;8(12):959–968.
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caracciolo G, Cavaliere C, et al. Shotgun proteomic analytical approach for studying proteins adsorbed onto liposome surface. Anal Bioanal Chem. 2011;401(4):1195–1202.
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Miranda OR, Moyano DF, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PloS One. 2011;6(9):e24374.
   PubMed Web of Science ®Google Scholar
• Caracciolo G, Pozzi D, Capriotti AL, et al. Lipid composition: a “key factor” for the rational manipulation of the liposome-protein corona by liposome design. RSC Adv. 2015;5(8):5967–5975.
   Web of Science ®Google Scholar
• Caracciolo G, Pozzi D, Capriotti AL, et al. The liposome-protein corona in mice and humans and its implications for in vivo delivery. J Mater Chem B. 2014;2(42):7419–7428.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178–181.
   PubMed Web of Science ®Google Scholar
• Hamilton A, Biganzoli L, Coleman R, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol. 2002;13(6):910–918.
   PubMed Web of Science ®Google Scholar
• Schottler S, Becker G, Winzen S, et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat Nanotechnol. 2016;11(4):372–377.
   PubMed Web of Science ®Google Scholar
• Pozzi D, Colapicchioni V, Caracciolo G, et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale. 2014;6(5):2782–2792.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172(1):38–47.
   PubMed Web of Science ®Google Scholar
• Parr MJ, Ansell SM, Choi LS, et al. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta. 1994;1195(1):21–30.
   PubMed Web of Science ®Google Scholar
• Pasut G, Paolino D, Celia C, et al. PEG-dendron phospholioids as innovative biomaterials for the preparation of super stealth liposomes for anticancer therapy. J Control Release. 2015;199:106–113.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36(6):892–899.
   PubMed Web of Science ®Google Scholar
• Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2008;25(1):55–71.
   PubMed Web of Science ®Google Scholar
• Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(2):219–233.
   PubMed Web of Science ®Google Scholar
• Molinaro R, Corbo C, Martinez JO, et al. Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater. 2016;15(9):1037–1046.
   PubMed Web of Science ®Google Scholar
• Husztik E, Lazar G, Parducz A. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol. 1980;61(6):624–630.
   PubMedGoogle Scholar
• Diagaradjane P, Deorukhkar A, Gelovani JG, et al. Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano. 2010;4(7):4131–4141.
   PubMed Web of Science ®Google Scholar
• Liu T, Choi H, Zhou R, et al. RES blockade: a strategy for boosting efficiency of nanoparticle drug. Nano Today. 2015;10(1):11–21.
   Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615–1626.
   PubMed Web of Science ®Google Scholar
• Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164(2):138–144.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–823.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Suri K, Yang Y, et al. Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces. 2014;114:294–300.
   PubMed Web of Science ®Google Scholar
• Hadjidemetriou M, Al-Ahmady Z, Mazza M, et al. In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles. ACS Nano. 2015;9(8):8142–8156.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Ferrari M, Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology. 2009;20(49):495101.
   PubMed Web of Science ®Google Scholar
• Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials. 2006;27(30):5307–5314.
   PubMed Web of Science ®Google Scholar
• Gentile F, Chiappini C, Fine D, et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech. 2008;41(10):2312–2318.
   PubMed Web of Science ®Google Scholar
• Kuwahara M, Sugimoto M, Tsuji S, et al. Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol. 2002;22(2):329–334.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664.
   PubMed Web of Science ®Google Scholar
• Adriani G, de Tullio MD, Ferrari M, et al. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials. 2012;33(22):5504–5513.
   PubMed Web of Science ®Google Scholar
• Sevick EM, Jain RK. Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res. 1989;49(13):3513–3519.
   PubMed Web of Science ®Google Scholar
• Godin B, Chiappini C, Srinivasan S, et al. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater. 2012;22(20):4225–4235.
   PubMed Web of Science ®Google Scholar
• van de Ven AL, Kim P, Haley O, et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release. 2012;158(1):148–155.
   PubMed Web of Science ®Google Scholar
• Xu R, Zhang G, Mai J, et al. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016;34(4):414–418.
   PubMed Web of Science ®Google Scholar
• von Maltzahn G, Park JH, Lin KY, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater. 2011;10(7):545–552.
   PubMed Web of Science ®Google Scholar
• Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137–143.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8):876–885.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–1053.
   PubMed Web of Science ®Google Scholar
• Chen N, Brachmann C, Liu X, et al. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol. 2015;76(4):699–712.
   PubMed Web of Science ®Google Scholar
• Kirui DK, Celia C, Molinaro R, et al. Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response. Adv Healthc Mater. 2015;4(7):1092–1103.
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release. 2013;167(2):130–137.
   PubMed Web of Science ®Google Scholar
• Jiang W, Huang Y, An Y, et al. Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano. 2015;9(9):8689–8696.
   PubMed Web of Science ®Google Scholar
• Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59(16):4129–4135.
   PubMed Web of Science ®Google Scholar
• Cham KK, Baker JH, Takhar KS, et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010;103(1):52–60.
   PubMed Web of Science ®Google Scholar
• Luan X, Guan YY, Lovell JF, et al. Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel. Biomaterials. 2016;95:60–73.
   PubMed Web of Science ®Google Scholar
• Huang Y, Stylianopoulos T, Duda DG, et al. Benefits of vascular normalization are dose and time dependent–letter. Cancer Res. 2013;73(23):7144–7146.
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452–464.
   PubMed Web of Science ®Google Scholar
• Zhang L, Nishihara H, Kano MR. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol Pharm Bull. 2012;35(5):761–766.
   PubMed Web of Science ®Google Scholar
• Meng H, Zhao Y, Dong J, et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013;7(11):10048–10065.
   PubMed Web of Science ®Google Scholar
• Yokoi K, Tanei T, Godin B, et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett. 2014;345(1):48–55.
   PubMed Web of Science ®Google Scholar
• Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54(13):3352–3356.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.
   PubMed Web of Science ®Google Scholar
• Eikenes L, Tufto I, Schnell EA, et al. Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res. 2010;30(2):359–368.
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–120.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22(12):2848–2854.
   PubMed Web of Science ®Google Scholar
• Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93.
   PubMed Web of Science ®Google Scholar
• Liu J, Liao S, Diop-Frimpong B, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA. 2012;109(41):16618–16623.
   PubMed Web of Science ®Google Scholar
• Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA. 2011;108(7):2909–2914.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA. 2013;110(46):18632–18637.
   PubMed Web of Science ®Google Scholar
• Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47(13):1955–1961.
   PubMed Web of Science ®Google Scholar
• Wilop S, von Hobe S, Crysandt M, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135(10):1429–1435.
   PubMed Web of Science ®Google Scholar
• Nakai Y, Isayama H, Ijichi H, et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs. 2013;31(5):1294–1299.
   PubMed Web of Science ®Google Scholar
• Ji T, Ding Y, Zhao Y, et al. Peptide assembly integration of fibroblast-targeting and cell-penetration features for enhanced antitumor drug delivery. Adv Mater. 2015;27(11):1865–1873.
   PubMed Web of Science ®Google Scholar
• Ji T, Zhao Y, Ding Y, et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew Chem Int Ed Engl. 2016;55(3):1050–1055.
   PubMed Web of Science ®Google Scholar
• Lu D, Wientjes MG, Lu Z, et al. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007;322(1):80–88.
   PubMed Web of Science ®Google Scholar
• Kovar JL, Johnson MA, Volcheck WM, et al. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol. 2006;169(4):1415–1426.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291–317.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–1070.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra39.
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750–763.
   PubMed Web of Science ®Google Scholar
• Hauert S, Berman S, Nagpal R, et al. A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today. 2013;8(6):566–576.
   PubMed Web of Science ®Google Scholar
• Harris TJ, von Maltzahn G, Lord ME, et al. Protease-triggered unveiling of bioactive nanoparticles. Small. 2008;4(9):1307–1312.
   PubMed Web of Science ®Google Scholar
• Caracciolo G, Cardarelli F, Pozzi D, et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1,2-dioleoyl-3-trimethylammonium propane/DNA nanoparticles. ACS Appl Mater Interfaces. 2013;5(24):13171–13179.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182–195.
   PubMed Web of Science ®Google Scholar
• Weissmann G. Lysosome. N Engl J Med. 1965 Nov 11;273(20):1084–90contd.
   PubMed Web of Science ®Google Scholar
• Sun-Wada GH, Wada Y, Futai M. Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell Struct Funct. 2003;28(5):455–463.
   PubMed Web of Science ®Google Scholar
• Botos E, Klumperman J, Oorschot V, et al. Caveolin-1 is transported to multi-vesicular bodies after albumin-induced endocytosis of caveolae in HepG2 cells. J Cell Mol Med. 2008;12(5A):1632–1639.
   PubMed Web of Science ®Google Scholar
• Gabrielson NP, Pack DW. Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J Control Release. 2009;136(1):54–61.
   PubMed Web of Science ®Google Scholar
• Li Y, Cheng Q, Jiang Q, et al. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. J Control Release. 2014;176:104–114.
   PubMed Web of Science ®Google Scholar
• Behr J. The proton sponge: a trick to enter cells the viruses did not exploit. Chimia. 1997;51:34–36.
   Web of Science ®Google Scholar
• Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev. 2011;40(1):233–245.
   PubMed Web of Science ®Google Scholar
• Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release. 2009;139(2):88–93.
   PubMed Web of Science ®Google Scholar
• Yue Y, Jin F, Deng R, et al. Revisit complexation between DNA and polyethylenimine - effect of uncomplexed chains free in the solution mixture on gene transfection. J Control Release. 2011;155(1):67–76.
   PubMed Web of Science ®Google Scholar
• Allende D, Simon SA, McIntosh TJ. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys J. 2005;88(3):1828–1837.
   PubMed Web of Science ®Google Scholar
• Ogris M, Carlisle RC, Bettinger T, et al. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem. 2001;276(50):47550–47555.
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323(5922):1718–1722.
   PubMed Web of Science ®Google Scholar
• Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol. 2009;10(3):218–227.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Hong K, et al. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6(5):271–279.
   PubMed Web of Science ®Google Scholar